A randomized, open-label, phase II trial comparing neoadjuvant endocrinetherapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitorinavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant earlybreast cancer- GeparPiPPa.

CLINICAL TRIAL WITH MEDICINES